NCT04177823View on ClinicalTrials.gov

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.

Trial Locations (1)

100191

GSK Investigational Site, Beijing